[go: up one dir, main page]

WO2003015781A1 - Nouvelles compositions pharmaceutiques antidiabetiques - Google Patents

Nouvelles compositions pharmaceutiques antidiabetiques Download PDF

Info

Publication number
WO2003015781A1
WO2003015781A1 PCT/JP2002/008276 JP0208276W WO03015781A1 WO 2003015781 A1 WO2003015781 A1 WO 2003015781A1 JP 0208276 W JP0208276 W JP 0208276W WO 03015781 A1 WO03015781 A1 WO 03015781A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pharmaceutical compositions
bonded
heteroaryl
novel antidiabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008276
Other languages
English (en)
Japanese (ja)
Inventor
Toshihiko Fujiwara
Shigeru Ushiyama
Tomio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of WO2003015781A1 publication Critical patent/WO2003015781A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques pour la prévention ou le traitement du diabète, ces compositions contenant comme ingrédient actif des composés représentés par la formule générale (I), ou bien des sels, des esters ou d'autres dérivés pharmacologiquement acceptables de ceux-ci. Dans la formule générale (I), A est un groupe benzène, pyridine, pyridazine, pyrimidine, pyrrole, furane, thiophène, pyrazole, imidazole, isoxazole ou isothiazole, chacun de ces groupes étant éventuellement substitué, R1 est un groupe aryle éventuellement substitué ou un groupe hétéroaryle éventuellement substitué, R2 est un groupe hétéroaryle azoté éventuellement substitué et R3 est un hétérocycle azoté monocyclique ou polycyclique pouvant être substitué, les atomes du constituant A auxquels R1 et R3 sont liés étant chacun adjacents à l'atome du constituant A auquel R2 est lié.
PCT/JP2002/008276 2001-08-15 2002-08-14 Nouvelles compositions pharmaceutiques antidiabetiques Ceased WO2003015781A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001246344 2001-08-15
JP2001-246344 2001-08-15

Publications (1)

Publication Number Publication Date
WO2003015781A1 true WO2003015781A1 (fr) 2003-02-27

Family

ID=19075908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008276 Ceased WO2003015781A1 (fr) 2001-08-15 2002-08-14 Nouvelles compositions pharmaceutiques antidiabetiques

Country Status (1)

Country Link
WO (1) WO2003015781A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (fr) * 2002-07-19 2004-01-29 Sankyo Company, Limited Compose amine tertiaire bicyclique insature
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
WO2011042389A3 (fr) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (fr) * 1999-07-21 2001-01-24 Sankyo Company Limited Dérivés de pyrrole hétéroaryl substitués, leur préparation et leur utilisation thérapeutique
WO2002057264A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company Limited Derives de pyrrole pour traiter des maladies dans lesquelles interviennent des cytokines
WO2002057265A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company, Limited Composes substitues avec des groupes amines bicycliques
WO2002057255A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company, Limited Derives du pyrrole substitues en 4 ou 5
JP2002284779A (ja) * 2001-01-18 2002-10-03 Sankyo Co Ltd ヘテロアリール置換ピロール誘導体を含有する医薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (fr) * 1999-07-21 2001-01-24 Sankyo Company Limited Dérivés de pyrrole hétéroaryl substitués, leur préparation et leur utilisation thérapeutique
JP2002284779A (ja) * 2001-01-18 2002-10-03 Sankyo Co Ltd ヘテロアリール置換ピロール誘導体を含有する医薬
WO2002057264A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company Limited Derives de pyrrole pour traiter des maladies dans lesquelles interviennent des cytokines
WO2002057265A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company, Limited Composes substitues avec des groupes amines bicycliques
WO2002057255A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company, Limited Derives du pyrrole substitues en 4 ou 5

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004009592A1 (fr) * 2002-07-19 2004-01-29 Sankyo Company, Limited Compose amine tertiaire bicyclique insature
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2011042389A3 (fr) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles
JP2013507334A (ja) * 2009-10-09 2013-03-04 バイエル・クロップサイエンス・アーゲー フェニルピリ（ミ）ジニラゾール類
EP2784071A1 (fr) * 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles et leur utilisation comme fongicides
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
EP3708179A1 (fr) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
EP4309673A2 (fr) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
EP4424697A2 (fr) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation

Similar Documents

Publication Publication Date Title
WO2006070208A8 (fr) Derives de pyrimidine en tant qu’agonistes des gpcr
IL164487A0 (en) 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides
WO2007101060A3 (fr) Composés pour le traitement de troubles métaboliques
WO2005097129A3 (fr) Compose de 6-azaindole
WO2007087505A3 (fr) Composés destinés au traitement des troubles du métabolisme
CA2424600A1 (fr) Composes aliphatiques azotes a noyau a cinq elements
WO2005105732A8 (fr) Composes methylaryl- ou heteroarylamides substitues
EP1698628A4 (fr) Derive d'hydroxypyrimidone presentant une activite d'inhibition de l'integrase du vih
NO20081821L (no) Forbindelser for behandling av metabolske forstyrrelser
WO2008111441A1 (fr) Composition pharmaceutique
EP1702919A4 (fr) Nouveau derive de benzimidazole a substitution 2-heteroaryle
WO2005000309A3 (fr) Composes chimiques
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
WO2004098496A3 (fr) Composes destines au traitement de troubles metaboliques
WO2004091486A3 (fr) Composes destines au traitement de troubles metaboliques
CA2336412A1 (fr) Medicament pour le traitement du diabete
CA2126465A1 (fr) Inhibiteurs de restenose apres une arterioplastie coronaire percutanee
WO2008153042A1 (fr) Agent antitumoral
WO2008056266A3 (fr) 8-pipéridinyl-2-pyridinylpyrimido[1,2-a]pirimidin-6-one substituée et dérivés de 8-pipéridinyl-2-pyrimidinylpyrimido[1,2-a]pyrimidin-6-one
WO2006127426A8 (fr) Derives heterocyliques et heteroaryle insecticide a substitution benzylamino
WO2003015781A1 (fr) Nouvelles compositions pharmaceutiques antidiabetiques
CA2626767A1 (fr) Derives heterocycliques de pyridine substitues et antifongique ainsi constitue
WO2007093292A3 (fr) Dérivés amino hétérocycliques et hétéroaryliques substitués à effet insecticide
EP1361225A4 (fr) Composes substitues avec des groupes amines bicycliques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP